On January 5, 2026, at 22:01 CET in Mechelen, Belgium, Galapagos NV (traded on Euronext & NASDAQ under GLPG) disclosed the conclusion of the works council consultation related to the cessation of cell therapy operations. Following this, the Board of Directors has approved the commencement of winding down the Company’s cell therapy ventures.